STOCK TITAN

Cbdmd Inc - YCBD STOCK NEWS

Welcome to our dedicated page for Cbdmd news (Ticker: YCBD), a resource for investors and traders seeking the latest updates and insights on Cbdmd stock.

Company Overview

cbdMD, Inc. (YCBD) is a U.S.-based specialty company that produces and distributes premium hemp-derived cannabidiol (CBD) products combined with innovative functional mushroom supplements. Established in 2015 and headquartered in Charlotte, North Carolina, the company has cultivated a diverse portfolio that caters to both individual and pet wellness. Its key brands, including cbdMD, Paw CBD, and ATRx Labs, exemplify its dedication to natural health solutions backed by stringent quality standards and science-based research.

Business Model & Distribution

Operating in the dynamic wellness and cannabinoid industries, cbdMD, Inc. employs a multi-channel distribution strategy that drives revenue through a variety of platforms. The company leverages its flagship e-commerce website along with third-party online retail sites, wholesalers, and brick-and-mortar retailers. This extensive distribution network not only enhances market reach but also positions the business to address the increasing consumer demand for U.S.-produced, THC-free CBD and related wellness products.

Product Portfolio & Innovation

The product lineup of cbdMD, Inc. is comprehensive and varied, designed to meet a broad spectrum of consumer needs. The core offerings under the cbdMD brand include CBD tinctures, gummies, topicals, capsules, bath products, and sleep aids that have been formulated to provide relief and enhance overall well-being. The Paw CBD brand extends the company's expertise to pet wellness with veterinarian-formulated tinctures, chews, and topicals tailored for various pet health requirements.

In addition to its established CBD offerings, the company has diversified its product base with the ATRx Labs brand. This division focuses on functional mushroom supplements that harness the benefits of natural extraction and modern formulation techniques. These supplements are designed to support cognitive function, immune response, and overall health, integrating naturally derived ingredients to appeal to wellness enthusiasts who seek alternatives to traditional products.

Market Position & Industry Expertise

In an industry that demands both innovation and compliance, cbdMD, Inc. stands out through its commitment to product quality and scientific integrity. The company adheres to stringent manufacturing standards in line with Farm Bill regulations, ensuring all its products are THC-free and safe for consumption. It incorporates advanced extraction methods and clinical research to validate the efficacy of its formulations, thereby building a reputation grounded in transparency and trustworthiness.

Operational Strategy & Competitive Advantages

  • Multi-Channel Distribution: A vast network including its own e-commerce platform, third-party websites, and physical retail locations ensures extensive market penetration.
  • Science-Backed Formulations: Products are developed using rigorous research and clinical trial data that support claims of safety and effectiveness.
  • Innovative Product Development: Continuous investment in R&D allows the company to diversify its product portfolio and respond to emerging consumer trends.
  • Quality and Regulatory Compliance: The company’s commitment to producing THC-free, Farm Bill-compliant products is central to its value proposition.
  • Operational Efficiency: Strategic cost management and expense optimization reflect the company’s focus on enhancing its operational stability without compromising product quality.

Consumer & Investor Considerations

cbdMD, Inc. prioritizes consumer safety and product efficacy through stringent quality control measures and adherence to relevant regulatory standards. By blending traditional wellness practices with modern scientific advancements, the company delivers products that are not only innovative but also reliable. Investors and market analysts can view cbdMD, Inc. as a noteworthy example of a business that combines diversified revenue streams, a broad product portfolio, and a commitment to quality—and scientific validation—to build trust and stakeholder confidence.

Conclusion

Overall, cbdMD, Inc. is positioned as a comprehensive provider of premium CBD and functional wellness solutions. Through a robust operational framework, multi-channel distribution, and a steadfast commitment to quality and research, the company continues to build an enduring legacy in the competitive wellness market. Its systematic approach to innovation and operational integrity makes it a key subject of interest for in-depth investment research and market analysis.

Rhea-AI Summary

cbdMD (NYSE American: YCBD) has scheduled a conference call to discuss its fourth quarter and fiscal year 2024 financial results and business progress. The call will take place on Tuesday, December 17, 2024, at 4:20 p.m. Eastern Time. Investors can access the call through USA/Canada (844-763-8274) or International (647-484-8814) numbers. A replay will be available with passcode 4840580, and a webcast replay will be accessible through January 17, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences earnings
-
Rhea-AI Summary

cbdMD (NYSE: YCBD) has launched Herbal Oasis Social Tonics, a new line of hemp-derived THC seltzers. Available in four flavors, each can contains 5mg THC, 5mg CBG, and adaptogenic mushrooms. The product features nano-liposomal technology for fast-acting effects within 10-15 minutes. According to Euromonitor International, the adult hemp beverage market reached $230 million in 2023, is expected to triple in 2024, and projected to exceed $4 billion by 2028. The products are currently available on cbdMD.com and in select markets in North Carolina and Alabama, with plans for broader distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.47%
Tags
none
-
Rhea-AI Summary

cbdMD, Inc. (NYSE American: YCBD) has received acceptance from NYSE American for its plan to regain compliance with continued listing standards by December 5, 2025. The company, known for its CBD brands cbdMD and Paw CBD, along with functional mushroom brand ATRx Labs, was previously found non-compliant with Section 1003(a)(ii) of the NYSE American Company Guide due to insufficient stockholders' equity and reported losses. cbdMD reported a stockholders' deficit of $3.1 million as of March 31, 2024, and losses in three of its four most recent fiscal years ended September 30, 2023.

During the plan period, cbdMD will undergo quarterly reviews to assess progress. If compliance is not achieved by the deadline or sufficient progress is not made, NYSE American may initiate delisting proceedings. The company's CEO, T. Ronan Kennedy, views this as a critical step in addressing capital structure challenges and re-engaging with Series A preferred shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
Rhea-AI Summary

cbdMD, Inc. (NYSE American: YCBD) reported financial results for Q3 2024 ending June 30, 2024. Key highlights include:

- Net sales of $5.1 million, down 15% YoY but up 18% sequentially
- Gross profit improved to 65% from 63% in Q3 2023
- Operating loss reduced to $0.38 million from $1.8 million in Q3 2023
- Net income of $0.46 million compared to a net loss of $1.7 million in Q3 2023
- Cash on hand increased to $2.3 million from $1.8 million at fiscal year-end 2023

The company achieved significant operational efficiencies, with SG&A expenses down and the best non-GAAP adjusted EBITDA result in its history. However, cbdMD received a non-compliance notice from NYSE American and must submit a plan to regain compliance by December 5, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
-
Rhea-AI Summary

cbdMD, Inc. (NYSE American: YCBD), a leading CBD company, has announced a conference call scheduled for August 14, 2024, at 4:20 p.m. Eastern Time. The call will discuss the company's third quarter fiscal 2024 financial results and business progress for the period ending June 30, 2024. Investors and interested parties can join the call using the following details:

- USA/Canada: 844-763-8274
- International: 647-484-8814
- Replay available: USA/Canada (877-344-7529), International (412-317-0088), Passcode: 5067217

A webcast replay will be accessible until August 14, 2025, via the provided link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.17%
Tags
conferences earnings
-
Rhea-AI Summary

cbdMD (NYSE: YCBD) announced the publication of its human clinical trial data in the Journal of the International Society of Sports Nutrition. The study, conducted by the University of South Carolina, evaluated the effects of daily intake of 100 mg of cbdMD's Broad Spectrum CBD blend over 12 weeks on healthy adults.

Key findings include significant pain reduction, improved psychological well-being in male participants, and reduced perceived stress in female participants. The study confirmed the safety and tolerability of the product, aligning with previous research on safe CBD consumption levels.

cbdMD highlighted the trial as evidence of their commitment to science, safety, and efficacy, reinforcing their leadership in the CBD industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
Rhea-AI Summary

cbdMD (NYSE American: YCBD) has received a noncompliance notice from NYSE American, indicating that the company does not meet the continued listing standards. As of March 31, 2024, the company reported stockholders' equity of $3.1 million, below the required $4 million. Additionally, it has reported losses in three of the last four fiscal years. cbdMD must submit a compliance plan by July 5, 2024, to regain compliance by December 5, 2025. Although the notice does not affect the company's immediate operations or trading status, the stocks will carry a "BC" designation for being below compliance. cbdMD aims to achieve profitability and has announced cost reductions to be implemented by August 2024. The company is also considering converting Preferred Stock liabilities to equity to meet compliance but is not assured of success.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
none
-
Rhea-AI Summary

cbdMD (NYSE American: YCBD) has launched the ATRx Labs Premium Mushroom Line exclusively at GNC stores nationwide. The line consists of four products targeting various health needs: Energy & Stamina, Memory & Cognition, Digestion & Microbiome, and Immune Support. Each supplement merges powerful mushroom extracts with clinically studied ingredients to support natural wellness. This strategic partnership with GNC aims to meet the increasing consumer demand for natural health solutions, marking cbdMD's expansion in the wellness sector beyond CBD products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Summary

On May 16, 2024, cbdMD announced its new Max Chill Dragon Fruit D9 Gummies, featuring a 1:1 CBD to THC ratio. Each gummy contains 10mg of Delta 9 THC and 10mg of CBD, aiming to provide balanced relaxation and stress relief. The gummies are vegan, gluten-free, and have a tropical dragon fruit flavor. Priced at $39.99, they are available on cbdMD's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
none
News
Rhea-AI Summary

cbdMD reported its financial results for Q2 of fiscal 2024, showing a slight increase in operational losses from $1.4 million to $1.5 million YoY. Net sales decreased by 30% to $4.4 million, with DTC sales dropping 26% and wholesale sales falling 44%. Despite these setbacks, the company launched its ATRx Platinum line in GNC stores, aiming to expand market presence. Cost-cutting measures are projected to save $2.4 million annually, potentially leading to positive cash flow by August. The company also closed $1.25 million in net financing through convertible notes. Net loss for the quarter was $4 million, or $1.35 per share, attributable to a non-cash contingency liability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags

FAQ

What is the current stock price of Cbdmd (YCBD)?

The current stock price of Cbdmd (YCBD) is $0.23 as of April 7, 2025.

What is the market cap of Cbdmd (YCBD)?

The market cap of Cbdmd (YCBD) is approximately 1.5M.

What type of products does cbdMD, Inc. offer?

cbdMD, Inc. offers a broad range of hemp-derived CBD products including tinctures, gummies, topicals, capsules, pet products, and functional mushroom supplements.

Which brands are operated by the company?

The company operates the cbdMD and Paw CBD brands for its CBD offerings and the ATRx Labs brand for its functional mushroom products.

How does the company distribute its products?

Products are distributed through the company’s e-commerce website, third-party online retailers, wholesalers, and traditional brick-and-mortar retail outlets across the United States.

What makes cbdMD, Inc. distinctive in the wellness market?

Its focus on science-backed product development, adherence to strict quality standards, and a diversified product portfolio in both CBD and functional mushroom segments distinguish cbdMD, Inc. in the competitive wellness market.

How does cbdMD ensure the safety and quality of its products?

The company follows rigorous manufacturing processes and quality control measures in compliance with Farm Bill regulations, ensuring that all products are THC-free and meet high safety standards.

What consumer segments does the company target?

cbdMD, Inc. targets wellness enthusiasts, pet owners, and consumers seeking natural health supplements and alternatives through both cannabinoid and functional mushroom products.

How is the company innovating in the CBD space?

Innovation is driven by continuous research and development efforts, including clinical trials and advanced formulation techniques that yield new products to meet diverse consumer health needs.

What advantages does the company have in the market?

Its multi-channel distribution, strong research foundation, commitment to quality, and ability to adapt to changing consumer trends provide cbdMD, Inc. with a competitive edge in the industry.
Cbdmd Inc

NYSE:YCBD

YCBD Rankings

YCBD Stock Data

1.48M
5.40M
13.79%
2.96%
7.74%
Drug Manufacturers - Specialty & Generic
Perfumes, Cosmetics & Other Toilet Preparations
Link
United States
CHARLOTTE